At 27, AstraZeneca Has a Touch of Melancholy.

 

The American-born British poet T.S. Eliot wrote in The Waste Land that April is the cruellest month. But for AstraZeneca right now, August is probably the cruellest.

 

In August, the British pharmaceutical giant released three pieces of news from lung cancer clinical trials — two good, one bad.

 

The good news came from two already-marketed blockbuster drugs: Enhertu, developed in collaboration with Daiichi Sankyo, and Orpathys, developed with Hutchison China MediTech, both in combination with Tagrisso, met their primary endpoints in late-stage trials. The bad news was that a highly anticipated experimental drug, volrustomig, failed in a Phase III trial.

 

After review, the independent Data Monitoring Committee concluded that volrustomig in combination with chemotherapy was unlikely to outperform Merck's Keytruda in combination with chemotherapy. The trial was therefore recommended for termination.

 

This piece of bad news seemed to overshadow the other two positives. But if one takes a longer view, the investor sentiment that erupted in August was not unfounded.

 

In the past few weeks, AstraZeneca's heart disease drug Wainua unexpectedly failed in a late-stage trial; the rare disease drug Ultomiris also failed to meet its primary endpoint. Earlier this year, the breast cancer drug camizestrant, which was aiming for market launch, was rejected by the FDA due to trial design issues.

 

This string of disappointments, compounded by M&A rumors in early August, left the market genuinely worried: Would a potential $400 billion merger with Bristol-Myers Squibb be a desperate misstep?

 

If one counts from the 1999 merger of Sweden's Astra and Britain's Zeneca, AstraZeneca is 27 years old this year. This pharma company in its prime is now looking a little blue.

 

Chapter 1: A Heavy Blow

 

As a bispecific antibody, volrustomig simultaneously blocks two key immune pathways, PD-1 and CTLA-4, aiming to enable T cells to attack tumors more precisely and more aggressively.

 

The mechanism sounds promising. PD-1 inhibitors and CTLA-4 inhibitors are both blockbuster products in their own right. Combining them into one molecule should theoretically create a synergistic effect. AstraZeneca had high hopes for volrustomig, positioning it across multiple cancer types — with Phase III trials advancing in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma.

 

However, theory remains theory.

 

eVOLVE-Lung02 was a global Phase III randomized open-label trial that enrolled 895 patients across 25 countries. The trial targeted metastatic non-small cell lung cancer patients whose tumors had PD-L1 expression below 50%.

 

These are patients whose response to existing immunotherapies is suboptimal. AstraZeneca wanted to fill that gap.

 

After a planned interim analysis, the independent Data Monitoring Committee concluded that in the PD-L1-negative (<1%) patient subgroup, the volrustomig plus chemotherapy regimen was unlikely to meet the dual primary endpoints of progression-free survival and overall survival.

 

In other words, volrustomig couldn't beat Keytruda.

 

Previously, Jefferies analyst Michael Leuchten had described volrustomig's success as a "long shot." If brought to market, it could have generated approximately $1.3 billion in annual revenue across all indications by 2032.

 

The odds of that bet paying off now look slimmer.

 

Nevertheless, volrustomig has not been completely abandoned. AstraZeneca said other Phase III trials in cervical cancer, head and neck squamous cell carcinoma, and mesothelioma will continue. Susan Galbraith, AstraZeneca's Executive Vice President of Oncology R&D, said the company would learn from this trial and is determined to continue developing new drugs through its industry-leading R&D pipeline.

 

But the failure still landed like a heavy blow to AstraZeneca's lung cancer strategy.

 

"Covering more than half of lung cancer patients by 2030" — this is AstraZeneca's ambition, and volrustomig, Enhertu, and Orpathys were all important parts of that plan.

 

With one of the three pillars collapsing, the pressure naturally shifts to other candidates — including its self-developed PD-1/TIGIT bispecific rilvegostomig, and the TROP2 ADC Datroway, developed in collaboration with Daiichi Sankyo.

 

Data from the Phase III Avanzar trial of Datroway in first-line lung cancer is expected to read out this year. The stakes are even higher now.

 

Chapter 2: A Legacy Hard to Sustain

 

AstraZeneca CEO Pascal Soriot has never been short of stories.

 

 

When he took the helm in 2012, the MNC was at a low point. Patent cliffs were approaching, revenue was declining, and morale was low. Two years later, U.S. pharmaceutical giant Pfizer made a $118 billion takeover offer.

 

The move triggered intervention from the British government, which was concerned about losing a major British company.

 

Soriot wasn't going to accept. His response at the time was that the acquisition could harm patients by distracting from and delaying the development of life-saving cancer drugs. "What do we say if someone's father dies of lung cancer because our drug was delayed?"

 

As it turned out, Soriot defended AstraZeneca.

 

Under this captain's leadership, AstraZeneca made big bets in oncology and revived a once-abandoned ovarian cancer drug, Lynparza. Soriot pushed forward the development of the lung cancer drug Tagrisso and laid out plans for the immunotherapy Imfinzi.

 

These bets paid off.

 

The media called Tagrisso AstraZeneca's "crown jewel." In the first half of 2026, its sales reached $3.775 billion. Imfinzi brought in $3.548 billion, up 29%. Enhertu, developed with Daiichi Sankyo, generated $2.961 billion in global sales in the first half of the year. Soriot had turned a struggling company into an oncology powerhouse.

 

In 2024, AstraZeneca's market capitalization exceeded £200 billion for the first time. Soriot set a revenue target of $80 billion by 2030. In the first half of 2026, total revenue reached $30.672 billion, up 6% year-over-year.

 

Everything seemed to be on track — except that mid-2026 has been anything but calm.

 

In early July, the heart drug Wainua failed in a late-stage trial, sending the stock tumbling. In July, the rare disease drug Ultomiris failed to meet its primary endpoint in a Phase III trial. Around the same time, AstraZeneca disclosed in its earnings report that two self-developed ADC programs were terminated due to disappointing data.

 

Then came August 3, when M&A rumors exploded.

 

Investors were stunned. Just months earlier, Soriot had told them that large-scale M&A was "really low on the probability scale." And yet, it turned out AstraZeneca was in talks with BMS about a merger.

On the day the news broke, AstraZeneca's stock plunged 9%.

 

One fund manager holding AstraZeneca shares called the deal "strategically and financially nonsensical." Another analyst said investors would oppose the idea because AstraZeneca's earnings per share growth was expected to exceed 10% over the next five years, while BMS's EPS could shrink over the entire decade.

 

Soriot was under pressure from two directions — pipeline setbacks and strategic questioning.

 

The failure of volrustomig was a major stumble in oncology. And this time, he didn't have the "savior" halo that protected him during the Pfizer takeover attempt.

 

Chapter 3: The Fear of Patent Cliffs

 

The BMS merger rumors came suddenly — and faded just as quickly.

 

According to the Financial Times, AstraZeneca and BMS had held multiple rounds of talks about a potential merger. If the deal had gone through, the new entity's market cap would have approached $400 billion, making it the largest merger in pharmaceutical history.

 

Investors voted with their feet. AstraZeneca's stock posted its biggest single-day drop since March 2020 — the COVID crash. To many outsiders, the deal looked like Soriot was panicking.

 

BMS is facing a severe patent cliff. The European patent for its anticoagulant Eliquis expired in May 2026, and U.S. exclusivity will be lost in April 2028, with annual revenue expected to decline by $1.5 to $2 billion starting in 2027. The cancer immunotherapy Opdivo saw its Q2 revenue slip 3% to $2.49 billion.

 

AstraZeneca, by contrast, is in its strongest financial cycle ever. Its oncology drugs generate about $25 billion in annual sales, accounting for nearly half of its revenue. The company is charging ahead.

 

So why take on a load that is facing a patent cliff?

 

 

Some analysts believe Soriot wanted to quickly scale up through M&A to achieve the $80 billion revenue target by 2030 — which would require nearly doubling from 2025's $58.7 billion. Others guessed he wanted to shift focus further toward the U.S. — AstraZeneca had already announced plans to list its ordinary shares on the NYSE, with the U.S. market contributing about 40% of revenue.

 

Unfortunately, investors weren't buying it.

 

BMO Capital Markets analysts noted significant overlap between the two companies in areas such as non-small cell lung cancer, "reducing the likelihood of the merger materializing." Mizuho analyst Jared Holz said: "Investors would view it as AstraZeneca not needing BMS; only the reverse would make sense."

 

The rumors were quickly denied. A senior source told Reuters there had been "no negotiations whatsoever" between the two companies. The stock recovered.

 

But the questions the episode raised haven't gone away.

 

Why would Soriot even consider such a deal? Were the words he said back when he rejected Pfizer — about the destructiveness of M&A, the distraction of scientists, and the harm to patients — still valid?

 

Perhaps the answer lies in the numbers. After all, the patent cliff is the pharmaceutical industry's cruelest reality. Tagrisso, Imfinzi, Enhertu — the blockbuster drugs that underpin AstraZeneca's glory today will eventually face patent expiration. Soriot knows this better than anyone.

 

Could BMS's predicament today be a mirror of AstraZeneca's tomorrow? This fear may explain that brief "flirtation" better than any strategic calculation.

 

Chapter 4: The Road Ahead

 

To be fair, at 27, AstraZeneca's fundamentals remain solid.

 

First-half 2026 revenue reached $30.672 billion, with oncology growing 15%. The three pillars of Tagrisso, Imfinzi, and Enhertu remain strong. The company reiterated its $80 billion revenue target for 2030.

 

Soriot said in the July earnings report that the company has "the scientific capabilities, R&D pipeline, and team needed to achieve this goal."

 

The problem is that the credibility of the pipeline is eroding. Before volrustomig's failure, Wainua fell, Ultomiris fell, and two ADCs were cut. This string of setbacks has led investors to question: How "industry-leading" is AstraZeneca's R&D pipeline really?

 

Where are the key focus points going forward?

 

First, there's rilvegostomig. This PD-1/TIGIT bispecific is seen as a key alternative after volrustomig's failure. It recently showed promising results in a Phase II trial for first-line non-small cell lung cancer, but the gap between Phase II and Phase III — volrustomig just filled that gap with a failure.

 

Second, Datroway. Although this TROP2 ADC, developed with Daiichi Sankyo, has already been approved, the real test lies in the Phase III Avanzar trial for first-line lung cancer, with data expected to read out this year. If successful, it will join Enhertu to form AstraZeneca's twin towers in the ADC space.

 

Then there's the oral GLP-1 candidate elecoglipron, which has initiated six Phase III trials for obesity and type 2 diabetes. Weight loss is the hottest track in pharma right now, and AstraZeneca doesn't want to be left behind.

 

Over the next 18 months, AstraZeneca is expected to receive more than 20 high-value clinical data readouts. R&D spending is projected to account for approximately 20% of total revenue in 2026.

 

But investors need more than "projections."

 

As IG Chief Technical Analyst Axel Rudolph put it: "While the fundamental investment case remains supported by solid fundamentals and a strong late-stage pipeline, AstraZeneca needs positive clinical progress to rebuild confidence."

 

The failure of volrustomig is a reminder that the pharmaceutical industry's cruelest reality has never changed: out of 10 drug candidates, 9 may fall by the wayside. AstraZeneca's success over the past decade has led many to forget this rule. Now it's back — in the form of a string of failures.

 

When Soriot rejected Pfizer in 2014, he said M&A would distract scientists, delay drug development, and hurt patients. But now, he himself seems to be considering M&A, and he's also under pressure from pipeline setbacks.

 

At 27, AstraZeneca stands at a delicate juncture. It is no longer the down-and-out aristocrat that needed to be saved, nor is it the unstoppable innovation machine. It is a mature pharma company with strong cash flow and blockbuster products, trying to find its next growth curve before the patent cliff arrives.

 

Soriot has walked this path once before — from the lows of 2012 to today's giant, it took him 14 years. Will the second time be smoother? Perhaps only the data readouts will tell.

 

References:

AstraZeneca touts Enhertu, Orpathys dual lung cancer wins amid bispecific failure

AstraZeneca Shares Fall on Deal Talks With Bristol-Myers

AstraZeneca Investors See Little Logic in Bristol Tie-Up

Pfizer Ends AstraZeneca Deal Amid Chinese Food, Sniping